CLINICAL DEVELOPMENT IN ONCOLOGY


CAR-T landscape set to expand in 2024


CAR-T therapy is an expensive form of cancer treatment, with costs that can reach millions of dollars per patient.


GLOBALDATA HEALTHCARE


Once reintroduced into the patient’s bloodstream, the modified cells seek out, attack and destroy cancer cells. Credit: Meletios Verras via Shutterstock.com.


A


ccording to GlobalData’s Clinical Trials Database, clinical trials of chimeric antigen receptor (CAR)-T


therapies peaked in 2021 with 272 taking place. There have been 217 clinical trials of CAR-T therapies up to July 2024, and GlobalData expects the year’s total number of trials to exceed those in 2021. CAR-T therapy is a type of immunotherapy that involves modifying a patient’s T-cells to


28 | Clinical Trials in Oncology


target and destroy cancer cells. This treatment has shown success in treating blood cancers such as leukaemia and lymphoma. T-cells are genetically altered in a lab to produce a receptor that targets specific proteins in cancer cells. Once reintroduced into the patient’s bloodstream, these modified cells seek out, attack and destroy cancer cells. US Food and Drug Administration-approved CAR-T therapies, such as Novartis’s Kymriah


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44